Skip to content
ZZ Biotech
  • Home
  • The Company
    • About Us
    • Scientific Advisory Board
    • Board of Directors
    • Management Team
    • 3K3A-Activated Protein C
    • Expanded Access
  • Stroke Program
    • Science & Clinical Program
    • Stroke Clinical Advisory Board
    • Scientific Papers
  • ALS Program
    • Science & Clinical Program
    • ALS Phase 2 Steering Committee
    • Scientific Papers
  • Wound Healing Program
    • Science & Clinical Program
    • Wound Healing Advisors
    • Scientific Papers
  • News
  • Contact
619.574.0820
Linkedin
ZZ Biotech
  • Home
  • The Company
    • About Us
    • Scientific Advisory Board
    • Board of Directors
    • Management Team
    • 3K3A-Activated Protein C
    • Expanded Access
  • Stroke Program
    • Science & Clinical Program
    • Stroke Clinical Advisory Board
    • Scientific Papers
  • ALS Program
    • Science & Clinical Program
    • ALS Phase 2 Steering Committee
    • Scientific Papers
  • Wound Healing Program
    • Science & Clinical Program
    • Wound Healing Advisors
    • Scientific Papers
  • News
  • Contact

The Company

Houston, TX, USA

+1 (619) 574 0820
kpryor@zzbiotech.com
Kent Pryor
ZZ Biotech, LLC
4265 San Felipe St.
Suite 1100
Houston, Texas
77027 USA

Sydney, NSW, Australia

+61 2 8599 8811
jhennock@zzbiotech.com
Jay Hennock
ZZ Biotech Pty Ltd.
Level 13, 234 George Street
Sydney NSW 2000
Australia

Recent News

  • ZZ Biotech Announces FDA Fast Track Designation for Stroke Program June 12, 2020
  • ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC January 29, 2018
  • Hope for reversing stroke-induced long-term disability August 22, 2016
  • Stem cell therapy heals injured mouse brain August 22, 2016
  • ZZ Biotech’s regenerative bio drugs manufactured in Brisbane with support of Biopharmaceuticals Australia July 6, 2016
© ZZ Biotech, LLC 2020